Even as 2nd-line drugs, sulfonylureas shown to be cardiotoxic with high rate of low blood glucoseRead More »
Production Assistant, Diabetes In Control
Patients who have normoglycemia still at risk for glucose spikes and diabetes.Read More »
Study investigates preservation or improvement of B-cell function using metformin with or without short-term insulin.Read More »
Guest Post by David Kliff, Editor, Diabetic Investor
This weekend, the most dedicated people in diabetes will gather in Baltimore for the AADE conference. Year after year, these amazing people gather to see all the latest toys in the toy chest, learn about all the new drugs, and share insights into how they are impacting the lives of the patients they work with.
Would you be more open to prescribing a GLP-1 Inhibitor if there was an oral product rather than an injectable? Follow the link to share your opinion and see what your colleagues think.Read More »
According to a recent study, frequently consuming meat, poultry, or fish cooked at high temperatures increases the risk for hypertension by how much?
Follow the link for the answer.Read More »
Man, 67 years of age, had been on GLP-1, SGLT-2, and metformin for over 4 years without difficulty or reported untoward side effects. He started taking the SGLT-2 before most health care professionals knew about the risk of DKA in people who have type 2 diabetes when taking SGLT-2s.Read More »
In this week's Homerun Slides, the conclusion of the pathophysiology of type 1 diabetes with the side effects of insulin and treating hypoglycemia.Read More »
International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #138: Pathogenesis of Type 2 Diabetes Mellitus Part 9
In summary, postbinding defects in insulin action primarily are responsible for the insulin resistance in T2DM. Diminished insulin binding, when present, is modest and secondary to downregulation of the insulin receptor by chronic hyperinsulinemia. In type 2 diabetic patients with overt fasting hyperglycemia, a number of postbinding defects have been demonstrated, including reduced insulin receptor tyrosine kinase activity, insulin signal transduction abnormalities, decreased glucose transport, diminished glucose phosphorylation, and impaired glycogen synthase activity. The glycolytic/glucose oxidative pathway is largely intact and, when defects are observed, they appear to be acquired secondary to enhanced FFA/lipid oxidation. From the quantitative standpoint, impaired glycogen synthesis represents the major pathway responsible for the insulin resistance in T2DM, and is present long before the onset of overt diabetes, that is, in normal glucose-tolerant, insulin-resistant prediabetic subjects and in individuals with IGT. The impairment in glycogen synthase activation appears to result from a defect in the ability of insulin to phosphorylate IRS-1, causing a reduced association of the p85 subunit of PI-3 kinase with IRS-1 and decreased activation of the enzyme PI-3 kinase.Read More »
How comfortable are you with prescribing a SGLT-2 inhibitor? Follow the link to see how you and your colleagues compare.Read More »